Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Kevin Bitterman sold 5,312 shares of the stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $79.95, for a total transaction of $424,694.40. Following the sale, the director owned 13,257 shares in the company, valued at $1,059,897.15. The trade was a 28.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kevin Bitterman also recently made the following trade(s):
- On Wednesday, October 21st, Kevin Bitterman sold 25,519 shares of Disc Medicine stock. The shares were sold at an average price of $80.23, for a total transaction of $2,047,389.37.
- On Monday, October 19th, Kevin Bitterman sold 10,994 shares of Disc Medicine stock. The shares were sold at an average price of $79.97, for a total transaction of $879,190.18.
- On Friday, September 11th, Kevin Bitterman sold 27,136 shares of Disc Medicine stock. The shares were sold at an average price of $70.11, for a total transaction of $1,902,504.96.
- On Friday, September 4th, Kevin Bitterman sold 1,689 shares of Disc Medicine stock. The stock was sold at an average price of $79.96, for a total transaction of $135,052.44.
- On Thursday, September 3rd, Kevin Bitterman sold 5,203 shares of Disc Medicine stock. The stock was sold at an average price of $79.98, for a total transaction of $416,135.94.
- On Wednesday, September 2nd, Kevin Bitterman sold 49,164 shares of Disc Medicine stock. The stock was sold at an average price of $80.17, for a total transaction of $3,941,477.88.
- On Tuesday, September 1st, Kevin Bitterman sold 129 shares of Disc Medicine stock. The shares were sold at an average price of $79.95, for a total transaction of $10,313.55.
Disc Medicine Stock Performance
Shares of NASDAQ:IRON opened at $76.00 on Thursday. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The stock has a market capitalization of $2.92 billion, a price-to-earnings ratio of -11.55 and a beta of 0.93. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The company's 50 day simple moving average is $71.44 and its 200 day simple moving average is $71.47.
Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.17. As a group, research analysts predict that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.
Hedge Funds Weigh In On Disc Medicine
A number of institutional investors have recently added to or reduced their stakes in IRON. BlackRock Inc. acquired a new position in Disc Medicine during the 2nd quarter worth approximately $180,502,000. Wellington Management Group LLP lifted its stake in Disc Medicine by 0.3% in the 2nd quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company's stock valued at $127,362,000 after purchasing an additional 5,975 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Disc Medicine by 191.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company's stock valued at $73,280,000 after purchasing an additional 735,300 shares during the last quarter. Opaleye Management Inc. boosted its position in Disc Medicine by 103.1% in the second quarter. Opaleye Management Inc. now owns 855,000 shares of the company's stock valued at $62,535,000 after buying an additional 434,000 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in Disc Medicine by 14.7% in the first quarter. Jennison Associates LLC now owns 610,382 shares of the company's stock valued at $39,028,000 after buying an additional 78,303 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Disc Medicine
Here are the key news stories impacting Disc Medicine this week:
- Positive Sentiment: Analyst price targets increased: Jefferies raised its price target to $149, while Cantor Fitzgerald lifted its target to $170 following positive Phase 3 results for bitopertin. The upgrades reinforce optimism about the drug’s potential in erythropoietic protoporphyria and related conditions. Jefferies raises Disc Medicine price target Cantor Fitzgerald raises Disc Medicine price target
- Positive Sentiment: $450 million financing strengthens the balance sheet: Disc Medicine priced an upsized offering of 6 million shares at $75 per share, with a possible 900,000-share overallotment. Proceeds will fund clinical development, research, and potential commercialization of bitopertin, potentially reducing financing risk and extending the company’s operating runway. Disc Medicine announces $450 million offering
- Neutral Sentiment: Unusually high options activity indicates elevated trading interest and expectations for volatility, but the report does not establish a clear directional signal. Disc Medicine sees unusually high options volume
- Negative Sentiment: Share dilution is weighing on the stock: The sale of 6 million new shares—following the previously announced $350 million offering—can reduce existing shareholders’ ownership percentage and create selling pressure around the $75 offering price.
- Negative Sentiment: Director selling adds an overhang: Director Kevin Bitterman sold a combined 41,825 shares for approximately $3.35 million across October 19–21, materially reducing his direct holdings. The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which makes them less informative about current management expectations but still represents potential supply. Disc Medicine insider transaction filing
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on IRON shares. BMO Capital Markets boosted their price target on Disc Medicine from $100.00 to $120.00 and gave the stock an "outperform" rating in a report on Monday. Wedbush upped their price objective on Disc Medicine from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Monday. Cantor Fitzgerald raised their price objective on Disc Medicine from $125.00 to $170.00 and gave the company an "overweight" rating in a research note on Monday. Jefferies Financial Group reaffirmed a "buy" rating and issued a $149.00 price objective on shares of Disc Medicine in a research note on Wednesday. Finally, Wells Fargo & Company lifted their target price on Disc Medicine from $86.00 to $124.00 and gave the company an "overweight" rating in a research report on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Disc Medicine presently has a consensus rating of "Moderate Buy" and an average target price of $122.70.
View Our Latest Research Report on IRON
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.
The company's pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
